Literature DB >> 18266607

Effect of human immunodeficiency virus Type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection.

Noah Kiwanuka1, Oliver Laeyendecker, Merlin Robb, Godfrey Kigozi, Miguel Arroyo, Francine McCutchan, Leigh Anne Eller, Michael Eller, Fred Makumbi, Deborah Birx, Fred Wabwire-Mangen, David Serwadda, Nelson K Sewankambo, Thomas C Quinn, Maria Wawer, Ronald Gray.   

Abstract

BACKGROUND: Human immunodeficiency virus type 1 (HIV-1) subtypes differ in biological characteristics that may affect pathogenicity.
METHODS: We determined the HIV-1 subtype-specific rates of disease progression among 350 HIV-1 seroconverters. Subtype, viral load, and CD4(+) cell count were determined. Cox proportional hazards regression modeling was used to estimate adjusted hazard ratios (HRs) of progression to acquired immunodeficiency syndrome (AIDS) (defined as a CD4(+) cell count of < or =250 cells/mm(3)) and to AIDS-associated death.
RESULTS: A total of 59.1% of study subjects had subtype D strains, 15.1% had subtype A, 21.1% had intersubtype recombinant subtypes, 4.3% had multiple subtypes, and 0.3% had subtype C. Of the 350 subjects, 129 (37%) progressed to AIDS, and 68 (19.5%) died of AIDS. The median time to AIDS onset was shorter for persons with subtype D (6.5 years), recombinant subtypes (5.6 years), or multiple subtypes (5.8 years), compared with persons with subtype A (8.0 years; P = .022). Relative to subtype A, adjusted HRs of progression to AIDS were 2.13 [95% confidence interval {CI}, 1.10-4.11] for subtype D, 2.16 [95% CI, 1.05-4.45] for recombinant subtypes, and 4.40 [95% CI, 1.71-11.3] for multiple subtypes. The risk of progression to death was significantly higher for subtype D (adjusted HR, 5.65; 95% CI, 1.37-23.4), recombinant subtypes (adjusted HR, 6.70; 95% CI, 1.56-28.8), and multiple subtypes (adjusted HR, 7.67; 95% CI, 1.27-46.3), compared with subtype A.
CONCLUSIONS: HIV disease progression is affected by HIV-1 subtype. This finding may impact decisions on when to initiate antiretroviral therapy and may have implications for future trials of HIV-1 vaccines aimed at slowing disease progression.

Entities:  

Mesh:

Year:  2008        PMID: 18266607     DOI: 10.1086/527416

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  136 in total

1.  Short communication: Colony-forming hematopoietic progenitor cells are not preferentially infected by HIV type 1 subtypes A and D in vivo.

Authors:  Caroline E Mullis; Amy E Oliver; Leigh Anne Eller; David Guwatudde; Amy C Mueller; Michael A Eller; Hannah Kibuuka; Merlin Robb; Thomas C Quinn; Andrew D Redd
Journal:  AIDS Res Hum Retroviruses       Date:  2012-02-02       Impact factor: 2.205

2.  Predicting the level of vaccine-induced cross-immunity necessary to eliminate HIV epidemics composed of multiple subtypes.

Authors:  David J Gerberry; Sally Blower
Journal:  AIDS       Date:  2010-06-19       Impact factor: 4.177

3.  Changes in the distribution of HIV type 1 subtypes D and A in Rakai District, Uganda between 1994 and 2002.

Authors:  Samantha A Conroy; Oliver Laeyendecker; Andrew D Redd; Aleisha Collinson-Streng; Xiangrong Kong; Fredrick Makumbi; Tom Lutalo; Nelson Sewankambo; Noah Kiwanuka; Ronald H Gray; Maria J Wawer; David Serwadda; Thomas C Quinn
Journal:  AIDS Res Hum Retroviruses       Date:  2010-10-06       Impact factor: 2.205

Review 4.  T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces.

Authors:  Bette T Korber; Norman L Letvin; Barton F Haynes
Journal:  J Virol       Date:  2009-05-13       Impact factor: 5.103

Review 5.  The challenge of HIV-1 subtype diversity.

Authors:  Barbara S Taylor; Magdalena E Sobieszczyk; Francine E McCutchan; Scott M Hammer
Journal:  N Engl J Med       Date:  2008-04-10       Impact factor: 91.245

6.  Prevalence of drug resistance mutations and HIV type 1 subtypes in an HIV type 1-infected cohort in rural Tanzania.

Authors:  Pax Masimba; Elimsaada Kituma; Thomas Klimkait; Edit Horvath; Marcel Stoeckle; Christoph Hatz; Erick Mossdorf; Emmanuel Mwaigomole; Salim Khamis; Boniphace Jullu; Salim Abdulla; Marcel Tanner; Ingrid Felger
Journal:  AIDS Res Hum Retroviruses       Date:  2013-09       Impact factor: 2.205

7.  Immune responses in Ugandan women infected with subtypes A and D HIV using the BED capture immunoassay and an antibody avidity assay.

Authors:  Andrew F Longosz; Charles S Morrison; Pai-Lien Chen; Eric Arts; Immaculate Nankya; Robert A Salata; Veronica Franco; Thomas C Quinn; Susan H Eshleman; Oliver Laeyendecker
Journal:  J Acquir Immune Defic Syndr       Date:  2014-04-01       Impact factor: 3.731

8.  Induction of HIV type 1 expression correlates with T cell responsiveness to mycobacteria in patients coinfected with HIV type 1 and Mycobacterium tuberculosis.

Authors:  David H Canaday; Mianda Wu; Shigou Lu; Htin Aung; Pierre Peters; Joy Baseke; Wilma Mackay; Harriet Mayanja-Kizza; Zahra Toossi
Journal:  AIDS Res Hum Retroviruses       Date:  2009-02       Impact factor: 2.205

9.  HIV-1 viral subtype differences in the rate of CD4+ T-cell decline among HIV seroincident antiretroviral naive persons in Rakai district, Uganda.

Authors:  Noah Kiwanuka; Merlin Robb; Oliver Laeyendecker; Godfrey Kigozi; Fred Wabwire-Mangen; Fredrick E Makumbi; Fred Nalugoda; Joseph Kagaayi; Michael Eller; Leigh Anne Eller; David Serwadda; Nelson K Sewankambo; Steven J Reynolds; Thomas C Quinn; Ronald H Gray; Maria J Wawer; Christopher C Whalen
Journal:  J Acquir Immune Defic Syndr       Date:  2010-06       Impact factor: 3.731

10.  Neruodevelopmental Outcomes in Preschool Children Living With HIV-1 Subtypes A and D in Uganda.

Authors:  Horacio Ruiseñor-Escudero; Alla Sikorskii; Itziar Familiar-Lopez; Deborah Persaud; Carrie Ziemniak; Noeline Nakasujja; Robert Opoka; Michael Boivin
Journal:  Pediatr Infect Dis J       Date:  2018-12       Impact factor: 2.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.